ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Starting soon · Phase 3

Conditions studied: Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS

In brief

Study Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT. It has a prospective, randomised, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design of up to 1,500 subjects with Acute Ischemic Stroke (AIS) who undergo EVT. Randomisation will be stratified by country/ region, and the IA thrombolytic agent (tenecteplase or alteplase). Minimal sufficient balance algorithm will operate within each stratum to preserve balance on key covariates while maintaining allocation randomness. Participants will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. Primary outcome data will be determined by simplified, structured method of assessment using the modified Rankin scale (mRS), conducted through centralized telephone interviews or online media performed by central trial personnel blinded to treatment assignment and received. Domain Interventions: The intervention group will receive a single dose of local intraarterial thrombolysis using either tenecteplase (at a dose of 0.0625mg/kg; maximum dose of 6.25mg) or alteplase (0.225 mg/kg; maximum dose, 20mg) at the end of EVT procedure plus standard of care while the control group will receive standard of care alone. The selection of the thrombolytic agent will be determined according to local availability. The dose of intraarterial thrombolysis will be increased if the above dose meets prespecified posterior probabilities at the first or second interims. In all eligible patients: 1. Local intra-arterial thrombolysis using either tenecteplase at a dose of 0.0625mg/kg "maximum dose of 6.25mg" or alteplase "0.225 mg/kg; maximum dose, 20mg\* 2. No intra-arterial thrombolysis. * The dose of IA thrombolysis may be doubled to 0.125 mg/kg tenecteplase or 0.45 mg/kg alteplase if this dose shows futility at pre-specified interims Randomization will be stratified by country/ region, the IA thrombolytic agent used (tenecteplase or alteplase). IA thrombolysis will be administered as a one-time treatment.

Key facts

Study ID

NCT07687056

Run by

University of Calgary

People needed

1500

Starts

2026-06-10

Expected to finish

2031-03-31

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Clinical diagnosis of stroke

You may not qualify if…

• There are no platform level exclusion criteria.

Where it is running

• The George Institute for Global Health — Sydney, Barangaroo, Australia
• University of Calgary- Foothills Medical Centre — Calgary, Alberta, Canada
• University of Alberta — Edmonton, Alberta, Canada
• Kelowna Regional Hospital — Kelowna, British Columbia, Canada
• Royal Columbian Hospital — New Westminster, British Columbia, Canada
• University of British Columbia — Vancouver, British Columbia, Canada
• University of Manitoba - Winnipeg Health Science Centre — Winnipeg, Manitoba, Canada
• Health Sciences North Horizon Sante-Nord — Greater Sudbury, Ontario, Canada
• Ottawa Civic Hospital — Ottawa, Ontario, Canada
• Sunnybrook Health Science Centre — Toronto, Ontario, Canada
• CHUM -Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec, Canada
• CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke) — Sherbrooke, Quebec, Canada
• Royal University Hospital — Saskatoon, Saskatchewan, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.